[1] Dekker E, Tanis PJ, Vleugels JLA, et al. Colorectal cancer [J]. Lancet, 2019, 394: 1467-1480. [2] 张学高. 中国卫生健康统计年鉴[M]. 北京: 中国协和医科大学出版社, 2017: 754-755. [3] Liang R, Liu Z, Piao X, et al. Research progress on GP73 in malignant tumors [J]. Onco Targets Ther, 2018, 11: 7417-7421. [4] Saxton RA, Sabatini DM. mTOR signaling in growth, metabolism, and disease [J]. Cell, 2017, 168: 960-976. [5] Wang XW, Zhang MYJ. Targeting mTOR network in colorectal cancer therapy [J]. World J Gastroenterol, 2014, 20: 4178-4188. [6] Chen X, Wang Y, Tao J, et al. mTORC1 up-regulates GP73 to promote proliferation and migration of hepatocellular carcinoma cells and growth of xenograft tumors in mice [J]. Gastroenterology, 2015, 149: 741-752. [7] Li J, Kim SG, Blenis J. Rapamycin: one drug, many effects [J]. Cell Metab, 2014, 19: 373-379. [8] Block KI, Block PB, Gyllenhaal C. Integrative treatment for colorectal cancer: a comprehensive approach[J]. J Altern Complem Med, 2018, 24: 890-901. [9] Menon S, Manning BD. Common corruption of the mTOR signaling network in human tumors [J]. Oncogene, 2008, 27: S43-S51. [10] Bürtin F, Mullins CS, Linnebacher M. Mouse models of colorectal cancer: past, present and future perspectives [J]. World J Gastroenterol, 2020, 26: 1394-1426. |